VALIANTLAB

Valiant Laboratories Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersALBERTDAVDHALEOSLABSZIMLABMEDICOMEDICAMEQANUHPHRAHCLWANBURY
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations182.1133.4237.5305.9
Other Income9.75.42.32.5
Total Income191.7138.8239.8308.5
Expenses
+ Cost of Materials Consumed169.4112.2190.8217.7
+ Purchases of Stock-in-Trade-0.50.69.016.0
+ Changes in Inventories-0.73.9-2.7-8.4
+ Employee Benefit Expense4.34.47.08.4
+ Finance Costs0.10.21.92.9
+ Depreciation & Amortisation2.02.16.08.4
+ Other Expenses17.917.126.939.1
Total Expenses192.5140.3239.0283.9
EBITDA-8.4-4.76.433.3
EBIT-10.4-6.80.424.9
Profit
PBT before Exceptional Items-0.8-1.50.824.5
Pretax Income-0.8-1.50.824.5
+ Current Tax-1.00.11.65.4
+ Deferred Tax-0.10.62.43.1
Tax Expense-1.10.74.08.5
Net Income0.3-2.2-3.316.0
+ Net Income — Continuing Ops0.3-2.2-3.316.0
+ Other Comprehensive Income0.2-0.00.00.0
Total Comprehensive Income0.5-2.2-3.316.0
Net Income to Common0.3-2.2-3.316.0
Per Share
Basic EPS0.13-0.51-0.512.95
Diluted EPS0.13-0.51-0.512.84
Other Comprehensive Income — detail
+ Other Comprehensive Income-0.00.0
+ Items NOT to be Reclassified to P&L0.2-0.0
+ Tax on Items NOT to be Reclassified0.0-0.0
+ Tax on Items NOT to be Reclassified — alt tag0.1
Comprehensive Income — Owners of Parent0.5-2.2-3.316.0
Per Share — as-filed variants
Basic EPS — Continuing Operations0.13-0.51-0.512.95
Diluted EPS — Continuing Operations0.13-0.51-0.512.84
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit13.816.840.380.7
Gross Margin %7.5812.5816.9726.39
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)-0.8-1.50.824.5
Net Income Adj (tax-effected)0.3-2.2-3.316.0
EPS Adj0.13-0.51-0.512.95
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.00
Paid Up Equity Capital43.543.554.354.3
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.